Exenatide-Induced Acute Pancreatitis
Abstract
Objective To report acute pancreatitis in a patient with non-insulin-dependent diabetes mellitus (NIDDM) receiving exenatide and critically review previous reports. Methods We describe clinical and laboratory data of a woman with probable exenatide-induced pancreatitis and apply the same criteria to previously published cases. Results A 64-year-old, nonalcoholic woman with NIDDM presented with a 1-month history of epigastric pain beginning 2 days after starting exenatide. Serum lipase concentration was 2700 U/L (reference range, 114-320 U/L), and serum amylase concentration was 131 U/L (reference range, 30-110 U/L). Liver function test results, lipid profile, and serum creatinine concentration were normal. Abdominal computed tomography (CT) showed changes consistent with pancreatitis, and the gallbladder was absent. Exenatide was discontinued. Conservative therapy resulted in rapid resolution of symptoms, normal lipase concentration (151 U/L), and normal findings from CT of the pancreas 90 days later. The US Food and Drug Administration has reported 36 cases of presumed pancreatitis associated with exenatide. However, none of the selection criteria were specified, two-thirds of the patients did not have CT, and 90% had at least 1 other risk factor for acute pancreatitis. A single published case report of exenatide-induced pancreatitis contains no description of the pancreas on abdominal CT, does not mention alcohol use, and does not report normal lipase values. Conclusions This is the most thoroughly documented example of probable exenatide-induced pancreatitis. In any diabetic patient with acute pancreatitis, exenatide must be ruled out as the cause and its use discontinued.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Case reports of acute pancreatitis occurred with the first approved GLP-1RA, exenatide b.i.d.
“This contrasts with case reports of acute pancreatitis with the first approved GLP-1RA, exenatide b.i.d. (64).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [64]
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · see citing works
Harrison's principles of internal medicine
(2008) · Choice Reviews Online · doi:10.5860/choice.46-0330 · Cited by 3,058 · see citing works
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works
Kolterman, O., Kim, D. D. H., Shen, L. Z., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434 · see citing works
Dore, D. D., Seeger, J. D., & Chan, K. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 324 · see citing works
Acute and chronic pancreatitis
Toskes, P. P., & Greenberger, N. J. (1983) · Disease-a-Month · doi:10.1016/0011-5029(83)90009-3 · Cited by 200 · see citing works
Exenatide (Exendin-4)–Induced Pancreatitis
Denker, P. S., & Dimarco, P. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-2043 · Cited by 140 · see citing works
Exenatide and Rare Adverse Events
Cure, P., Pileggi, A., & Alejandro, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707137 · Cited by 134 · see citing works
Drug-Induced Acute Pancreatitis
Kaurich, T. (2008) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2008.11928366 · Cited by 120 · see citing works
Serum lipase levels in nonpancreatic abdominal pain versus acute pancreatitis.
Gumaste, V. V., Roditis, N., Mehta, D., & Dave, P. B. (1993) · PubMed · Cited by 116 · see citing works
Algorithms for assessing the probability of an Adverse Drug Reaction
Doherty, M. J. (2009) · Respiratory Medicine CME · doi:10.1016/j.rmedc.2009.01.004 · Cited by 87 · see citing works
Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide
Dungan, K. M., & Buse, J. B. (2005) · Clinical Diabetes · doi:10.2337/diaclin.23.2.56 · Cited by 50 · see citing works
Yadav, D. K., & Dhir, R. (2006) · Pancreas · doi:10.1097/00006676-200611000-00240 · Cited by 25 · see citing works
Pancreatic enzymes in uremic patients with or without dialysis
Lin, X., Chen, T.-W., Wang, S.-S., Shiesh, S., Tsai, Y., Huang, T., Lee, S., & Ting, S. W.-K. (1988) · Clinical Biochemistry · doi:10.1016/0009-9120(88)90009-4 · Cited by 22 · see citing works
Pancréatite aiguë liée au glimépiride (Amarel®)
Duboeuf, T., Widerspach-Thor, A. D., Scotto, B., & Bacq, Y. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)94947-0 · Cited by 8 · see citing works
[Laser resection of a pedunculated giant lipoma of the esophagus].
Lesage, X., Kt, N., Notteghem, B., Chevalier, D., Delmotte, J. S., & Jf, C. (1992) · PubMed · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · see citing works
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358 · see citing works
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Garg, R., Chen, W. C., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 319 · see citing works
Gier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255 · see citing works
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145 · see citing works
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
Engel, S. S., Williams‐Herman, D., Golm, G. T., Clay, R. J., Machotka, S. V., Kaufman, K. D., & Goldstein, B. J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02382.x · Cited by 143 · see citing works
Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives
Borse, S., Chhipa, A. S., Sharma, V., Singh, D. P., & Nivsarkar, M. (2020) · Medical Principles and Practice · doi:10.1159/000511002 · Cited by 134 · see citing works
Wolfe, D. M., Kanji, S., Yazdi, F., Barbeau, P., Rice, D. B., Beck, A., Butler, C., Esmaeilisaraji, L., Skidmore, B., Moher, D., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231883 · Cited by 118 · see citing works
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series
Kenny, P. R., Brady, D. E., Torres, D. M., Ragozzino, L., Chalasani, N., & Harrison, S. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.363 · Cited by 106 · see citing works
Vrang, N., Jelsing, J., Simonsen, L., Jensen, A. E., Thorup, I., Søeborg, H., & Knudsen, L. B. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00182.2012 · Cited by 92 · see citing works
Thomsen, R. W., Pedersen, L., Møller, N., Kahlert, J., Beck-Nielsen, H., & Sørensen, H. T. (2015) · Diabetes Care · doi:10.2337/dc13-2983 · Cited by 89 · see citing works
Romley, J. A., Goldman, D. P., Solomon, M. D., McFadden, D. L., & Peters, A. L. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0075 · Cited by 85 · see citing works
Ever-increasing diversity of drug-induced pancreatitis
Weissman, S. I., Aziz, M., Perumpail, R. B., Mehta, T. I., Patel, R., & Tabibian, J. H. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i22.2902 · Cited by 73 · see citing works
Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
Butler, P. C., Matveyenko, A. V., Dry, S., Bhushan, A., & Elashoff, R. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1591-5 · Cited by 69 · see citing works
Anti-Inflammatory Properties of Exenatide in Human Pancreatic Islets
Cechin, S. R., Pérez-Álvarez, I., Fenjves, E., Molano, R. D., Pileggi, A., Berggren, P.-O., Ricordi, C., & Pastori, R. L. (2012) · Cell Transplantation · doi:10.3727/096368911x576027 · Cited by 67 · see citing works
Ayoub, M., Chela, H. K., Amin, N. A., Hunter, R., Anwar, J., Tahan, V., & Daglilar, E. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030944 · Cited by 73 · see citing works
Gurney, K., MacConell, L., Brown, C. J., & Han, J. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s28387 · Cited by 61 · see citing works
Acute pancreatitis due to diabetes: The role of hyperglycaemia and insulin resistance
Solanki, N. S., Barreto, S. G., & Saccone, G. T. P. (2012) · Pancreatology · doi:10.1016/j.pan.2012.01.003 · Cited by 60 · see citing works
Gurney, K., MacConell, L., Malloy, J. L., Zhou, M., & Kolterman, O. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s77290 · Cited by 45 · see citing works
Vildagliptin-Induced Acute Pancreatitis
Girgis, C. M., & Champion, B. L. (2011) · Endocrine Practice · doi:10.4158/ep10383.cr · Cited by 43 · see citing works
High fat diet and GLP-1 drugs induce pancreatic injury in mice
Rouse, R. L., Xu, L., Stewart, S. R., & Zhang, J. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.01.021 · Cited by 42 · see citing works
Pancreatitis: A Potential Complication of Liraglutide?
Franks, A. S., Lee, P. H., & George, C. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q789 · Cited by 34 · see citing works
Guo, H., Guo, Q., Li, Z., & Wang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1461398 · Cited by 35 · see citing works
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40 · see citing works
“This contrasts with case reports of acute pancreatitis with the first approved GLP-1RA, exenatide b.i.d. (64).”
Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 29 · see citing works
Lee, W., Kipp, Z. A., Pauss, S. N., Martinez, G. J., Bates, E. A., Badmus, O. O., Stec, D. E., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20242825 · Cited by 30 · see citing works
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 27 · see citing works
Emerging role of GLP-1 receptor agonists in the treatment of obesity
Neff, L. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s6816 · Cited by 26 · see citing works
Emerging role of GLP-1 receptor agonists in the treatment of obesity
Neff, L. M. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s6816 · Cited by 16 · see citing works
GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion
Yang, Y., Yu, X., Huang, L., & Yu, C. (2013) · Pancreatology · doi:10.1016/j.pan.2013.07.281 · Cited by 15 · see citing works
Weight Management in Type 2 Diabetes Mellitus
Siram, A. T., Yanagisawa, R. T., & Skamagas, M. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20208 · Cited by 14 · see citing works
Roy, D., Chadwick, K. D., Tatarkiewicz, K., LaCerte, C., Bergholm, A., Brodie, T., Mangipudy, R. S., Parkes, D. G., Graziano, M. J., & Reilly, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12294 · Cited by 13 · see citing works
Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer
Cases, A. I., Ohtsuka, T., Kimura, H., ZHENG, B., Shindo, K., Oda, Y., Mizumoto, K., Nakamura, M., & Tanaka, M. (2015) · Oncology Reports · doi:10.3892/or.2015.4138 · Cited by 14 · see citing works
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 13 · see citing works
The path to approval of new drugs for diabetes
Rendell, M. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.770470 · Cited by 12 · see citing works
Gene expression signature: a powerful approach for drug discovery in diabetes
Sithara, S., Crowley, T. M., Walder, K. R., & Aston‐Mourney, K. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0515 · Cited by 12 · see citing works
Usborne, A. L., Byrd, R. A., Meehan, J., Blackbourne, J. L., Sullivan, J., Poitout‐Belissent, F., Préfontaine, A., Martin, J. A., & Vahle, J. L. (2015) · Toxicologic Pathology · doi:10.1177/0192623315596857 · Cited by 12 · see citing works
Dose-dependent pancreatitis risk associated with GLP-1 agonists
Gu, J. H., & Samarneh, M. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01552-x · Cited by 10 · see citing works
Figat, M., Kardas, G., Kuna, P., & Panek, M. (2022) · Brain Sciences · doi:10.3390/brainsci12081090 · Cited by 10 · see citing works
Incretin-Based Therapies: Facing the Realities of Benefits Versus Side Effects
Lebovitz, H. E. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0274 · Cited by 7 · see citing works
Vildagliptin for the treatment of diabetes
Samraj, G. P. N. (2011) · Therapy · doi:10.2217/thy.11.75 · Cited by 4 · see citing works
Li, G., Long, X., Pan, Y., Xiao, M., & Zhao, X. (2018) · Biomedical Research - India · doi:10.4066/biomedicalresearch.29-17-3436 · Cited by 4 · see citing works
Clinical Efficacy of Colesevelam in Type 2 Diabetes Mellitus
Brunetti, L., & Campbell, R. K. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011406125 · Cited by 3 · see citing works
Toxicology Assessment of a Dual-Function Peptide 5rolGLP-HV in Mice
Ni, Z., Wang, B., Ma, X., Duan, H., Jiang, P., Li, X., Wei, Q., Ji, X., & Li, M. (2016) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-016-2166-9 · Cited by 3 · see citing works
Williams, J. A. (2014) · doi:10.3998/panc.2014.7 · Cited by 3 · see citing works
Liu, H., huang, S., Chen, S., Liang, S., Huang, M., Li, S., Xu, Y., & Xie, B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1725842 · Cited by 3 · see citing works
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-62635-6.00042-5 · Cited by 2 · see citing works
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32042-3 · Cited by 2 · see citing works
Sitagliptin-associated Acute Pancreatitis: A Case Report
Tsai, L.-Y., Ma, W.-Y., Hsia, T., Pei, D., & Su, C. (2011) · 內科學誌 · doi:10.6314/jimt.2011.22(4).06 · Cited by 1 · see citing works
New and Future Medications for the Treatment of Type 2 Diabetes Mellitus
Mathers, M. C., Zarbock, S. D., & Sutton, E. (2013) · American Journal of Lifestyle Medicine · doi:10.1177/1559827613498694 · Cited by 1 · see citing works
Incretin-Based Therapy and Pancreatitis—What is the Risk?
Sternthal, E. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.334 · Cited by 1 · see citing works
Sun, Y. Q., Guo, C. Y., Li, Q., Guo, L., Chen, L., Wang, W., & Zhang, J. C. (2018) · Biomedical Research - India · doi:10.4066/biomedicalresearch.29-17-2708 · Cited by 1 · see citing works
Evaluation of Dapagliflozin's Impact in Type 2 Diabetes Management as A Supplement to Metformin
Azhar, S., Chaudhary, A. J., Jafri, S. H., & Ejaz, U. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs20221611537 · Cited by 1 · see citing works
Incretin-Based Treatment Strategy - GLP-1 Receptor Agonists (GLP-1R) or So-Called Incretin Mimetics
Perušičová, J., & Owe, K. (2011) · InTech eBooks · doi:10.5772/21873
Andréasson, S. (2015) · Epsilon Archive for Student Projects (University of Southampton)
Bazarbekovna, B. R., Bektayeva, I. S., Konyrbayeva, A. B., Omarova, M. M., Abseitova, D. K., Kazbekova, A., Suslova, I. A., Moldasheva, A. T., Balazhanova, N. E., & Abdazimova, S. M. (2018) · Journal Medicine · doi:10.31082/1728-452x-2018-198-12-41-54
Current awareness: Pharmacoepidemiology and drug safety
(2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1854
Williams, J. A. (2021) · doi:10.3998/panc.2021.06
Vijayanand, M., & Patil, K. K. (2026) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-026-10870-y
- Authors
- Ayoub, W. A., Kumar, A. A., Naguib, H. S., & Taylor, H. C.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Ayoub, Walaa A.
- ORCID
- Kumar, Ashok A.
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 16
- Issue
- 1
- Pages
- 80-83
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W1998922126
- Cited by
- 58
- References
- 17
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2022: 4 · 2020: 3 · 2018: 3 · 2016: 2 · 2015: 5 · 2014: 5 · 2013: 4 · 2012: 6
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- exenatide, acute pancreatitis, drug-induced pancreatitis, type 2 diabetes, GLP-1 receptor agonists, serum lipase, abdominal CT, adverse drug reactions
- MeSH terms
- Exenatide, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Middle Aged, Pancreatitis, Peptides, Tomography, X-Ray Computed, Venoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
